Cancer Today Editors’ Picks: 2024
Our favorite Cancer Today stories from 2024, as picked by the editors.
Progress Against Cancer
Our favorite Cancer Today stories from 2024, as picked by the editors.
The Cancer Today editors share the most impactful reporting on cancer research from 2024.
In 2024, the American Association for Cancer Research (AACR) released the 14th edition of the annual AACR Cancer Progress Report and the third edition of the biennial AACR Cancer Disparities Progress Report that highlight...
The FDA approved the kinase inhibitors encorafenib and cetuximab plus chemotherapy for the treatment of certain colorectal cancers. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to encorafenib (Braftovi), in combination...
The FDA approved the mesenchymal stromal cell therapy remestemcel-L-rknd for some pediatric patients as young as 2 months. The U.S. Food and Drug Administration (FDA) has approved remestemcel-L-rknd (Ryoncil) for the treatment of...
The FDA approved ensartinib for certain patients with locally advanced or metastatic non-small cell lung cancer. The U.S. Food and Drug Administration (FDA) has approved ensartinib (Ensacove) for adults with non-small cell lung cancer...
Researchers at the 2024 San Antonio Breast Cancer Symposium discussed considerations for treating and managing of early-onset breast cancer.
Chest radiation may not be necessary for people with intermediate-risk breast cancer.
Active surveillance of DCIS patients may be an alternative to treatment, and guidelines add self-test for HPV.
The FDA approved cosibelimab-ipdl for certain skin cancers that cannot be treated with surgery or radiation. The U.S. Food and Drug Administration (FDA) has approved cosibelimab-ipdl (Unloxcyt) for the treatment of adult patients with...
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More